Examples
|
| Imuran | azathioprine (AZA) | |
| Trexall | methotrexate (MTX) | |
| CellCept | mycophenolate mofetil | |
| Prograf | tacrolimus | |
| Thalomid | thalidomide | |
| Purinethol | 6-mercaptopurine (6-MP) | |
How It Works
Immunomodulator medicines, such as
azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate, weaken or
suppress the
immune system.
These medicines are used
most often to prevent the body from rejecting a newly transplanted organ, but
they are also helpful in treating inflammatory bowel disease (IBD).
Why It Is Used
Immunomodulators are used for
inflammatory bowel disease (IBD) that:
- Has not responded to other
treatments.
- Can be controlled only with long-term use of
corticosteroids. Immunomodulators may be used so that the doctor can lower the
dose of corticosteroids that a person is taking. This is called "steroid
sparing."
How Well It Works
Immunomodulator medicines are
effective against inflammatory bowel disease. AZA and 6-MP are used to maintain
remission (a period without symptoms) in ulcerative
colitis and Crohn's disease. Both medicines are effective in treating
fistulas in Crohn's disease.
Crohn's disease
It may take 4 months or more for
azathioprine (AZA) and 6-mercaptopurine (6-MP) to improve symptoms. These
medicines are used to keep a person in remission and allow the person to stop
using
corticosteroids. These are the most commonly used
immunomodulators. They usually work well, but the disease often comes back
after you stop taking the medicine.1 Methotrexate
improves symptoms more quickly than 6-MP, but it has not been studied as
extensively.
A few studies have shown that methotrexate stops the
symptoms of
Crohn's disease and keeps the disease in
remission.1 Usually,
methotrexate is used when azathioprine (AZA) and 6-mercaptopurine (6-MP) don't
work.
Tacrolimus can be used in Crohn's disease when
corticosteroids do not work or fistulas develop. It also may be applied
topically for Crohn's disease that affects the mouth or
perineal area.2
Mycophenolate mofetil has been studied in active Crohn's disease, with
mixed results. More research is needed to confirm its role.3
Thalidomide has been shown to work in
Crohn's disease when corticosteroids did not. It has also been used to treat
fistulas. Controlled studies still need to be done.
There is some worry about serious side effects of thalidomide.1
Ulcerative colitis
Azathioprine (AZA) and
6-mercaptopurine (6-MP) are used for moderate to severe
ulcerative colitis to keep symptoms of the disease
from coming back after a person has reached a period without symptoms (remission).
Azathioprine has been shown
to keep 80% to 90% of people in remission for over 2 years. It also allows
people to stop taking corticosteroids.4
Oral azathioprine (taken by mouth) is used with steroids or cyclosporine
for moderate or severe colitis. Using azathioprine to maintain remission in
this way reduces the chances that symptoms will come back. It also makes it
less likely that a person will need a colectomy.4
Side Effects
Side effects of immunomodulator medicines
include:
- Nausea, vomiting, diarrhea, or stomach
ulcers.
- Rash.
- General feeling of being ill
(malaise).
- Liver inflammation.
Rare side effects include:
- Suppression of blood cell production (bone
marrow suppression), which may increase the risk of infection or serious
bleeding. Return to normal blood cell production may take several weeks after
the medicine is stopped.
- Fever.
- Inflammation of the
pancreas (pancreatitis). This may occur with AZA and 6-MP.
Extremely rare side effects of azathioprine include a
possible increased risk of cancer. Mycophenolate mofetil may increase the risk
of cancer of the lymph system (lymphoma) and other types of cancer.
See Drug Reference for a full list of side effects. (Drug Reference is
not available in all systems.)
What To Think About
Regular blood tests are needed to
check for effects that these medicines may have on the bone marrow, liver, and
kidneys.
Immunomodulator medicines are less likely than
corticosteroid medicines to cause growth failure in children.
Since these medicines weaken or suppress the immune system, they increase
your risk of infection.
If you are pregnant or want to become
pregnant, talk to your doctor about whether you can take immunomodulator
medicines. Some of these medicines are used in pregnancy but only when the
benefit outweighs the potential risk of harm to the fetus. Methotrexate,
mycophenolate mofetil, and thalidomide should not be used because they can
cause birth defects and pregnancy loss.
Complete the new medication information form (PDF)
(What is a PDF document?)
to help you understand this medication.
References
Citations
Friedman S, Lichtenstein GR (2006). Crohn's disease. In MM Wolfe et al., eds., Therapy of Digestive Disorders, 2nd ed., pp. 785-801. Philadelphia: Saunders Elsevier.
Sands BE (2006). Crohn's disease. In M Feldman et al.,
eds., Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 8th ed., vol. 2, pp. 2459-2498. Philadelphia: Saunders Elsevier.
Hanauer SB, Dassopoulos T (2001). Evolving treatment
strategies for inflammatory bowel disease. Annual Review of Medicine, 52: 299-318.
Friedman S, Lichtenstein GR (2006). Ulcerative colitis. In MM Wolfe et al., eds., Therapy of Digestive Disorders, 2nd ed., pp. 803-817. Philadelphia: Saunders Elsevier.
Credits
| Author | Monica Rhodes |
| Editor | Kathleen M. Ariss, MS |
| Associate Editor | Pat Truman, MATC |
| Primary Medical Reviewer | Kathleen Romito, MD - Family Medicine |
| Specialist Medical Reviewer | Jerome B. Simon, MD, FRCPC, FACP - Gastroenterology |
| Last Updated | October 9, 2008 |
Friedman S, Lichtenstein GR (2006). Crohn's disease. In MM Wolfe et al., eds., Therapy of Digestive Disorders, 2nd ed., pp. 785-801. Philadelphia: Saunders Elsevier.
Sands BE (2006). Crohn's disease. In M Feldman et al.,
eds., Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 8th ed., vol. 2, pp. 2459-2498. Philadelphia: Saunders Elsevier.
Hanauer SB, Dassopoulos T (2001). Evolving treatment
strategies for inflammatory bowel disease. Annual Review of Medicine, 52: 299-318.
Friedman S, Lichtenstein GR (2006). Ulcerative colitis. In MM Wolfe et al., eds., Therapy of Digestive Disorders, 2nd ed., pp. 803-817. Philadelphia: Saunders Elsevier.